Compare BWB & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWB | KMDA |
|---|---|---|
| Founded | 2005 | 1990 |
| Country | United States | Israel |
| Employees | 322 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.4M | 460.3M |
| IPO Year | N/A | 2013 |
| Metric | BWB | KMDA |
|---|---|---|
| Price | $19.36 | $7.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $21.67 | $14.00 |
| AVG Volume (30 Days) | ★ 54.4K | 54.0K |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.57 | $13.94 |
| Revenue Next Year | $12.35 | $9.84 |
| P/E Ratio | ★ $12.97 | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.79 | $6.50 |
| 52 Week High | $20.30 | $9.35 |
| Indicator | BWB | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 61.06 | 28.92 |
| Support Level | $17.65 | $6.87 |
| Resistance Level | $20.30 | $7.41 |
| Average True Range (ATR) | 0.53 | 0.14 |
| MACD | 0.05 | -0.06 |
| Stochastic Oscillator | 90.51 | 0.56 |
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.